---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-189932"
form_type: "8-K"
ticker: "MDXG"
cik: "0001376339"
company_name: "MIMEDX GROUP, INC."
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:19:02.534083+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MiMedx Q2 revenue $87M (+7% YoY), GAAP EPS $0.12, Adjusted EBITDA margin 23%

## Summary
- Net sales $87M, up 7% YoY; GAAP net income $18M, EPS $0.12.
- Adjusted EBITDA $20M, margin 23% vs 17.4% in Q2 2023.
- CEO reports competitive pressure from high-priced skin substitutes causing employee and customer attrition.
- Launched HELIOGEN (first xenograft) and commenced RCT for EPIEFFECT.
- Cash $69M; 2024 net sales growth guided to mid-to-high single digits.

## SEC filing metadata
- accession: 0001193125-24-189932
- form_type: 8-K
- ticker: MDXG
- cik: 0001376339
- company_name: MIMEDX GROUP, INC.
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1376339/000119312524189932/0001193125-24-189932-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1376339/000119312524189932/d866445d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-189932
- JSON: https://secwatch.observer/filing/0001193125-24-189932.json
- Plain text: https://secwatch.observer/filing/0001193125-24-189932.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.